Project Goal: A recombinant antibody to canine IgG as quickly as possible
We utilized a single immunization and generated hybridoma on Day 10. On Day 21, antibodies binding to canine IgG were identified through solid phase ELISA.
Candidate wells were expanded and rescreened for specificity to canine compared to human IgG. For accelerated expression, we sequence a mixed population and pairwise express all possible heavy and light chain combinations to identify the best antibodies.
Two candidate wells were sequenced using our rapid VH/VL sequencing, which confirmed a mixed population with two heavy chains in one well and three in the second. Since we screened only for IgG antibodies, the IgM were eliminated as possible binders. The remaining heavy chain sequences were expressed with each light chain.
Recombinant antibody derived from each parental well validated canine IgG binding. We compare the different heavy and light chain combinations for titer and affinity using biolayer interferometry and efficiency of purification to identify the best combination for the customer. After completing the characterization, the customer can be ready to move forward with large scale production in less than 2 months.